Serum chemokine (CC motif) ligand 2 (CCL2) was previously measured in 379 patients (255 had PC) undergoing prostate biopsy and it was found that CCL2 may be a novel biomarker to predict OS in PC, including metastatic cases [17,18]. Here, CCL2 is linked to pachyonychia congenita.